Share

August 2018; 8 (4) The Nerve! Readers Speak

Reader Response: Practice Current: How do you treat neuromyelitis optica?

Jagannadha Avasarala
First published August 13, 2018, DOI: https://doi.org/10.1212/CPJ.0000000000000497
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
419

Share

A few lingering questions on this topic.1

  1. I find it strange that Ocrevus, a CD20 blocker, is akin to Rituxan but not even on the map for treatment of neuromyelitis optica spectrum disorder (NMOSD), although Rituxan has been extensively used for this disease.

  2. What is double-negative (Ab) NMOSD? Does it exist?

  3. One hopes that there are better guidelines for monitoring CD19 cell counts (how frequent, endpoints, pitfalls, variations between end-stage disease and early-onset disease, if any).

  4. Pregnancy vs disease-modifying drugs in NMOSD is characterized by paucity of data. We need better data. Also, data collected will hopefully be openly shared among researchers so that there are many minds working on the same topic instead of a select few.

Footnotes

  • Author disclosures are available upon request (ncpjournal{at}neurology.org).

  • See response

References

  1. 1.↵
    1. Ganesh A
    . Practice Current: how do you treat neuromyelitis optica? Neurol Clin Pract 2017;7:170–178.
    OpenUrlAbstract/FREE Full Text

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me

Recommended articles